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Abstract: Various landmark studies have revealed structures and functions of the Sec61/SecY com-
plex in all domains of live demonstrating the conserved nature of this ancestral protein translocase.
While the bacterial homolog of the Sec61 complex resides in the plasma membrane, the eukaryotic
counterpart manages the transfer of precursor proteins into or across the membrane of the endoplas-
mic reticulum (ER). Sec61 complexes are accompanied by a set of dynamically recruited auxiliary
proteins assisting the transport of certain precursor polypeptides. TRAP and Sec62/Sec63 are two
auxiliary protein complexes in mammalian cells that have been characterized by structural and
biochemical methods. Using these ER membrane protein complexes for our proof-of-concept study,
we aimed to detect interactions of membrane proteins in living mammalian cells under physiological
conditions. Bimolecular luminescence complementation and competition was used to demonstrate
multiple protein–protein interactions of different topological layouts. In addition to the interac-
tion of the soluble catalytic and regulatory subunits of the cytosolic protein kinase A, we detected
interactions of ER membrane proteins that either belong to the same multimeric protein complex
(intra-complex interactions: Sec61α–Sec61β, TRAPα–TRAPβ) or protein complexes in juxtaposition
(inter-complex interactions: Sec61α–TRAPα, Sec61α–Sec63, and Sec61β–Sec63). In the process, we
established further control elements like synthetic peptide complementation for expression profiling
of fusion constructs and protease-mediated reporter degradation demonstrating the cytosolic local-
ization of a reporter complementation. Ease of use and flexibility of the approach presented here will
spur further research regarding the dynamics of protein–protein interactions in response to changing
cellular conditions in living cells.
Keywords: bimolecular luminescence complementation; competition; split luciferase; membrane
proteins; protein–protein interactions; Sec61 complex; Sec63; synthetic peptide complementation;
TRAP complex; ER protein translocase
1. Introduction
As the fundamental unit of life, cells endow biological systems with tremendous pow-
ers and astonishing features. In the case of differentiated eukaryotic cells, these are often
compartmentalized and different membrane-surrounded or membrane-less organelles help
to shape cellular fitness, metabolism, and signaling. One of the organelles that supports
both intracellular signaling, for example calcium (Ca2+) signaling or the unfolded protein
response, and secretion of proteohormones is the endoplasmic reticulum (ER) [1–4]. A
major membrane protein at the crossroad of ER signaling and protein transport is the
heterotrimeric Sec61 complex acting as the pore-forming component of the ER protein
translocase [5–7].
Many different membrane-spanning (~5000) and soluble (~3000) proteins of the hu-
man proteome can be guided by the Sec61 complex to enter the secretory pathway [8].
To meet the demands for the transport of such topologically diverse precursor proteins
crosslinking and native gel electrophoresis studies have demonstrated the dynamic associ-
ation of the Sec61 complex with accessory factors to form the active holo-translocon [9–12].
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For example, structural and proteomic data as well as pulling force studies verified the
hetero-tetrameric translocon-associated protein (TRAP) complex as an important player
supporting the Sec61 complex during co-translational transport of precursor proteins
with an above-average glycine-plus-proline content in the signal peptide [13–15]. Sim-
ilarly, the proteins Sec62/Sec63 were identified to support post-translational as well as
substrate-specific co-translational opening of the Sec61 complex [9,16–21]. In analogy to
enzyme-catalyzed reactions, auxiliary protein complexes like TRAP or Sec62/Sec63 act as
allosteric effectors supporting the gating of the Sec61 complex [22].
As exemplified above for the Sec61 complex, protein translocation machineries of
other organelles like the PIM complex of peroxisomes [23], the TIM/TOM complexes of
mitochondria [24], or the TIC/TOC equivalents in chloroplasts [25] all represent large,
heteromultimeric assemblies and their activity depends on protein–protein interactions
(PPI) [26,27]. The necessity of protein multimerization for proper functionality is by
no means restricted to protein translocation machineries and governs pivotal cellular
processes like DNA replication and transcription, mRNA translation, transmembrane
signaling mechanisms or enzymatic catalysis, and ATP production with estimates of up
to 80% of proteins operating in complexes [28,29]. Typically, PPI control the assembly
of protein complexes via non-covalent contacts between the side chains of amino acids
from different polypeptide strands and can form large-scale networks, often referred to
as the interactome [30,31]. Many methods have been developed to identify interactions of
proteins and define the interactome of cells. With regard to the experimental setup, those
methods can be classified as in vitro, in vivo, or in silico and include popular examples like
coimmunoprecipitation, the yeast-two-hybrid system, and structure-based prediction via
algorithms, respectively. However, method-specific strengths and weaknesses depending
on the scientific question asked is a feature they all share [29,32–34]. One of the more
challenging aspects when studying PPI is their dynamic nature that can trigger the transient
or stable formation of homo- or heterooligomers whose association can be influenced by
various cellular cues. A textbook example of a dynamic PPI of a heterooligomer regulated
by cellular cues is the protein kinase A (PKA). PKA represents a soluble tetramer of
two catalytic subunits harboring kinase function and two regulatory subunits that act
as cAMP sensors. Separation of the catalytic from the regulatory subunits activates the
kinase function and is influenced by intracellular (cAMP) and extracellular (hormones, e.g.,
glucagon) cues, which together with the corresponding hormone receptor and adenylate
cyclase represent critical elements of a signal transduction pathway [35]. Bimolecular
protein-fragment complementation assays are well suited to detect the spatiotemporal
dynamics of binary PPI like that of PKA in intact living cells. These assays are based on
proteinaceous split reporters with the complementary reporter fragments genetically fused
to proteins of interest, whose interaction can be directly visualized [36].
Here we used bimolecular luminescence complementation (BiLC) as live cell assay
to further complement the studies that so elegantly demonstrate the association of the
Sec61 complex with the TRAP complex or Sec62/Sec63 either in silico, in vitro, or after
reconstitution or vitrification. In the case of BiLC, the interaction of tagged protein pairs
reassembles a functional, split luciferase and can be visualized upon addition of a luciferase
substrate [37,38]. After verifying the dynamic PPI of the catalytic and regulatory subunits
of PKA, our proof-of-concept shows “intra-complex” interactions between subunits of
the Sec61 complex (Sec61α–Sec61β) as well as of the TRAP complex (TRAPα–TRAPβ).
Furthermore, we demonstrate “inter-complex” interactions between membrane proteins of
different complexes such as Sec61α–TRAPα, Sec61α–Sec63, and Sec61β–Sec63. Both types
of PPI, intra- and inter-complex ones, can be perturbed by competitive over-expression
of untagged variants. Alternatively, interactions of membrane or soluble protein pairs
that rely on reassembly of the split luciferase components in the cytosol are abolished by
the combination of plasma membrane permeabilization and trypsin-mediated reporter
degradation.
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2. Results
To reliably verify the PPI of ER membrane proteins in living cells, we established a
microplate reader–based bimolecular protein-fragment complementation assay widely
used for investigations of protein interactions [33]. The split reporter used here is an
optimized variant of the catalytic subunit of the luciferase derived from deep sea luminous
shrimp called NanoLuc [38]. The 19 kDa polypeptide consisting of a ten-stranded β-barrel
topology is separated after the ninth β-barrel providing an 18 kDa and 1 kDa fragment
called LgBiT and SmBiT, respectively. Although the two fragments can reconstruct a
functional luciferase that provides a bright luminescence in the presence of its substrate
furimazine, the engineered LgBiT and SmBiT show a low intrinsic affinity for each other.
The association constant of LgBiT and SmBiT has a kD of 190 µM, which is above the kD of
most physiological relevant PPI [37]. Thus, when LgBiT and SmBiT are added as fusion
tags to proteins of interest, luminescence will occur if two prerequisites are met: (i) the
presence of furimazine and (ii) direct interaction, i.e., close proximity of the proteins of
interest (Figure 1A).
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intensity after furimazine addition, cf. Figure 1C) were plotted. (C) Twenty-four hours post transfection with the rPKA-
CL and cPKA-CS reporter pair, cells were subjected to the indicated treatment regimens (circled numbers). Nine minutes 
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Figure 1. Establishing a bimolecular luminescence complementation assay based on protein kinase A and cell permeabilization.
(A) Principle of the bimolecular luminescence complementation (BiLC) assay. The upper cell shows the expression of two
interacting proteins, the regulatory and catalytic subunit of protein kinase A (rPKA and cPKA), C-terminally (C) tagged with
the LgBiT (L) and SmBiT (S) fragment of the luciferase, respectively. Protein–protein interaction reassembles a functional
luciferase (g owing green/blue sph re) that emits light upon addi ion of the substrate furimazin (not shown). In contrast,
expression of non-interacti g pro ins (lowe c ll) prevents functional reassembly of the luciferase and l minesc nce. (B) In
addition to untreated and mock treated cells, total luminescence (LU) was also measured from single or double transfected cells
using the rPKA-CL, cPKA-CS, or Halo-CS fusion constructs. For each condition and the corresponding biological replicates,
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the signals recorded 4 min after addition of furimazine (this time point usually depicts the peak intensity after furimazine
addition, cf. Figure 1C) were plotted. (C) Twenty-four hours post transfection with the rPKA-CL and cPKA-CS reporter pair,
cells were subjected to the indicated treatment regimens (circled numbers). Nine minutes after starting the measurement,
the addition of furimazine stimulated luminescence. After 19 min, cells were treated with forskolin (15 µM) to activate
adenylate cyclases and cAMP production, causing disassembly of the PKA subunits. DMSO served as vehicle control.
After 29 min, cells were treated in a reciprocal fashion; the ones that received DMSO first now received forskolin and vice
versa. Measurements were normalized to the signal intensity recorded 4 min after furimazine application and plotted as
relative luminescence units (RLU). (D) As in (C), but after substrate application, cells were treated with digitonin (0.002%) to
permeabilize the plasma membrane and trypsin (50 µg/mL) to digest the reporter and other cytosolic proteins. DMSO and
water treatments served as vehicle controls for digitonin and trypsin, respectively. Vertical gray bars in the line diagrams
represent manual 1 min application periods without luminescence readings. The dotted lines are extrapolated based on
the last and first data points before and after application. CL, C-terminally located LgBiT tag; CS, C-terminally located
SmBiT tag.
2.1. Establishing the NanoBiT Assay Based on the cAMP-Dependent Protein Kinase A, Forskolin,
and Semi-Permeabilization
The interacting regulatory and catalytic subunits of protein kinase A (rPKA, cPKA)
were C-terminally tagged with the LgBiT (L) and SmBiT (S) fragments, respectively. Cor-
responding fusion constructs were called rPKA-CL and cPKA-CS. The non-interacting
HaloTag-based fusion construct Halo-CS served as negative control (Figure 1A). HeLa cells
were seeded in a 96-well format and left untreated or were transfected for 24 h. Besides
mock transfection, cells were transfected with the plasmid encoding for rPKA-CL alone or
in combination with either Halo-CS or cPKA-CS. Four minutes after addition of furimazine,
the luminescence units (LU) of the five conditions were measured. As expected, strong
luminescence was detected only for the bona fide interacting fusion proteins rPKA-CL and
cPKA-CS providing a more than 600-fold brighter luminescence than the rPKA-CL and
Halo-CS pair (Figure 1B). The reversibility of the rPKA and cPKA interaction was demon-
strated using forskolin, a non-selective activator of most adenylate cyclase isoforms [39].
Conversion of ATP to cAMP by forskolin-activated adenylate cyclases caused the rapid
disassembly of rPKA from cPKA. Accordingly, forskolin treatment 10 or 20 min after
addition of the NanoLuc substrate furimazine induced a rapid decrease of luminescence
(Figure 1C). As depicted by the vertical gray bars in Figure 1C the addition of furimazine
and all other substances required their manual application and caused a short measurement
gap that was kept constant using a time window of one minute. The same applies to other
measurements shown later. We also tweaked the system for the use of larger, membrane-
impermeable effectors including soluble enzymes such as trypsin. Cells expressing the
rPKA-CL and cPKA-CS reporter pair as representation of a verified PPI were first subjected
to permeabilization of the plasma membrane by digitonin and subsequently treated with
trypsin for proteolytic cleavage of the reporter proteins to eliminate luminescence. As
shown in the line graphs in Figure 1D, addition of the substrate caused a sharp increase
in luminescence within 4 to 5 min (treatment 1). Somewhat surprisingly, the application
of digitonin for permeabilization of the plasma membrane (treatment 2, red or blue line)
further increased signal intensity. We attributed this effect to improved access of the bulky
furimazine substrate to the re-assembled luciferase. The subsequent addition of the pro-
tease trypsin after 40 min (treatment 3, red line) or 70 min (treatment 4, blue or black line)
eliminated luminescence almost entirely due to protease-mediated digestion of the fusion
proteins (Figure 1D). Of note, trypsin treatment of intact cells prior to permeabilization
did not cause a significant drop in luminescence due to reporter degradation or eventual
detachment of adherent cells from the microplate surface (cf. Figures 5B and 6B, blue lines).
Correspondingly, using a non-proteolytic enzyme like RNase A further corroborated the
specific elimination of luminescence by trypsin-mediated reporter degradation (Figure S1).
This line of experiments showed the applicability and dynamics of the BiLC system
for cytosolic interaction partners in living cells. Permeabilization of the plasma membrane
by digitonin also granted access of otherwise membrane-impermeable agents including
large biological effectors such as trypsin.
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2.2. Expression Profiling via Synthetic Complementation Using Chemically Synthesized Low and
High Affinity Oligopeptides
An often-ignored issue with protein-fragment complementation assays is the sufficient
expression of fusion constructs and synthesis of the encoded fusion proteins, which is
equally relevant for constructs encoding soluble and membrane proteins. Therefore, before
applying BiLC to ER membrane proteins, we deconstructed the system and designed an
assay for measuring expression of the LgBiT fusion constructs, when the LgBit is located in
the cytosol (Figure 2A). Instead of expressing the 11 amino acids (aa) long SmBiT peptide
as a fusion construct in parallel with a LgBiT fusion protein, we chemically synthesized
the SmBiT peptide and dissolved it in DMSO (Figure S2A). During synthesis, the SmBiT
peptide was N-terminally extended by a single cysteine for further downstream processes
(see below). Like the 11 + 1 aa SmBiT peptide, we also synthesized a scrambled version
thereof and an independent actin peptide (16 aa) as two negative controls that should not
reconstitute a functional luciferase in presence of a genetically expressed LgBiT fusion
protein. Using the semi-permeabilization protocol with digitonin (cf. Figure 1D), cells
expressing the rPKA-CL construct were provided 100 µM of a negative control peptide
(scrambled or actin) or the SmBiT. As expected, only upon the addition of the SmBiT
peptide did a complementation with rPKA-CL occur (Figure 2B). Three points are worth
emphasizing. One, taking into consideration the inefficient association between LgBiT and
SmBiT (kD = 190 µM) the use of a high peptide concentration like 100 µM was anticipated.
Two, titrating the concentrations of the SmBiT peptide (1, 10, 100 µM) showed a clear
dose-dependence of complementation and luminescence. Three, even at a concentration of
100 µM, the synthetic SmBiT provided a 10-fold lower signal intensity than the genetically
expressed PPI pair rPKA-CL and cPKA-CS (Figure 2B, dark blue versus gray line).
During the initial mutational screens for low affinity versions of the SmBiT, Dixon
and colleagues also reported variants with exceptionally high affinities for the LgBiT in
the nanomolar range [37]. For one of the variants the glutamates in position 8 and 9
of the original SmBiT undecapeptide were exchanged by lysines. We also synthesized
this peptide and based on its high affinity called it HaBiT (Figure S2A). As shown in
Figure 2C, after semi-permeabilization, HaBiT was also suited for expression profiling
of the rPKA-CL construct in a dose-dependent manner. Due to the high affinity, HaBiT
interacted with rPKA-CL in a concentration range from 10 to 100 nM providing efficient
luminescence (Figures 2C and S2C). At 100 nM the HaBiT signal exceeded that of the
genetically encoded reporter pair rPKA-CL and cPKA-CS. Combining the data of dose-
dependence and tested concentrations for the synthetic SmBiT and HaBiT peptide, the
latter showed an approximately 10,000-fold higher activity in the expression profiling assay
(Figure 2D). Taken together, both peptides SmBiT and HaBiT can be used to verify and
compare steady-state expression of generated fusion constructs.
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the luciferase substrate was added (treatment 1) and followed by 0.002% digitonin (treatment 2) and 
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controls able to reconstitute the functional luciferase. (B,C) Twenty-four hours post transfection with
rPKA-CL, the measurements of luminescence units (LU) were started. At the indicated times, the
luciferase substrate was added (treatment 1) and followed by 0.002% digitonin (treatment 2) and
the addition of the peptide with the indicated final concentration (treatment 3). The scrambled and
unrelated actin peptide were used as negative controls. Cells transfected with the genetically encoded
rPKA-CL plus cPKA-CS reporter pair were used for comparison of signal intensity and treated with
DMSO instead of peptide as last treatment. Vertical gray bars in the line diagrams represent manual
1 min application periods without luminescence readings and dotted lines are extrapolated based on
the last and first data points before and after indicated treatments. Each trace is the average of at least
three replicates. Note that traces for the reporter pair as well as the scrambled and actin peptide are
the same in (B) and (C). (D) Summary of the recorded signals 4 min after peptide supplementation
for each condition and repeat. CL, C-terminally located LgBiT tag; Digi, digitonin; Pep, peptide.
2.3. Verifying Expression of LgBit Fusion Constructs of ER Protein Translocase Subunits via
Synthetic Peptide Complementation
Before testing the PPI of ER membrane proteins in living cells, the synthetic comple-
mentation approach was used to verify synthesis of the LgBiT fusion proteins 24 h post
transfection. In addition to the cytosolic positive control rPKA-CL, five N- or C-terminally
LgBiT-tagged ER membrane proteins were tested including Sec61α, Sec61β, TRAPα, and
TRAPβ (Figure 3A). The latter two are classical type I membrane proteins with one Nexo-
Ccyto transmembrane helix (TMH) and a cleavable signal peptide [40]. Sec61β is a type
IV or tail-anchored membrane protein with a single TMH at the very C-terminus inserted
in an Ncyto-Cexo orientation [41]. Sec61α has 10 TMH with its N- and C-terminus located
in the cytosol [42]. All six of the LgBiT fusion proteins were tested with three different
peptides (cf. Figure 2A). While the scrambled peptide served as negative control and for
normalization, the SmBiT and HaBiT peptide served as positive controls that allowed
reconstitution of a functional luciferase in case the LgBiT fusion construct was properly ex-
pressed. Taking the different affinities of SmBiT and HaBiT for the LgBiT into consideration,
different peptide concentrations had to be used. Scrambled and SmBiT were added to a
final concentration of 100 µM, whereas HaBiT was used at 100 nM (Figure 3B). Despite the
three orders of magnitude lower concentration of HaBiT, it provided a 5–10-times stronger
signal in all six tested synthetic complementations. The strongest signal was achieved
in combination with the cytosolic rPKA-CL. Compared to the scrambled peptide, four
out of five LgBiT-tagged membrane protein fusions (Sec61α-NL, Sec61β-CL, TRAPα-CL,
TRAPβ-CL) provided a more than 10-fold stronger luminescence when complemented with
SmBiT peptide. Only the Sec61α-CL protein showed lower complementation efficiency
of ~2 relative luminescent units (RLU), likely caused by its lower abundance (Figure 3B).
When the HaBiT peptide was used in combination with the ER membrane protein fusions,
the RLU were at least 50-fold higher in comparison to the scrambled peptide, with the ex-
ception of the Sec61α-CL protein peaking at 15 RLU. Thus, the synthetic complementation
approach substantiated the plasmid-driven production of the LgBiT-tagged ER membrane
proteins with the Sec61α-CL protein providing a low complementation likely reflecting the
limited synthesis or stability of this fusion protein.
Despite its ER luminally located LgBiT tag, the Sec61β-CL protein also responded
strongly using the SmBiT or HaBiT peptide after semi-permeabilization (Figure 3). While
an inverted topology of Sec61β-CL could be one explanation, other reasons might entail
unintentional permeabilization of the ER membrane by digitonin or the active transport
of the synthetic oligopeptides into the ER by the transporter associated with antigen
processing, TAP [43]. As soon as more sensors with luminally located LgBiT tags are
available, further experiments will test the impact of TAP, permeabilization, and orientation
more systematically.
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Figure 3. Expression profiles of LgBit-tagged components of the ER protein translocase. (A) Topology
of the four ER membrane proteins (Sec61α/β, TRAPα/β) used for generating five LgBiT fusions. (B)
Twenty-four hours post transfection, the expression of the indicated LgBiT fusion constructs tagged
at the N- or C-terminus (NL or CL) was verified using the ynthetic complementation approach with
the scrambled, SmBiT, and HaBiT peptide, as d monstrated in Figur 2. The light intensity 4 min
after peptide addition was plotted as relative luminescent units (RLU). For each experiment and
tested fusion protein, the luminescence measured 4 min after complementation with the scrambled
peptide was used for normalization and set to 1. To depict the variation of the individual scrambled
peptide readings the average luminescence of this condition was used for its normalization. CL,
C-terminally located LgBiT tag; NL, N-terminally located LgBiT tag.
2.4. Validating Expression of SmBit Fusion Constructs via Western Blotting Using a Polyclonal
Antibody Raised against the SmBiT
The BiLC approach relies on the presence of both types of fusion proteins allowing the
1:1 stoichiometric interaction of the LgBiT and SmBiT tags. After confirming expression of
the LgBiT-tagged constructs via synthetic complementation (Figure 3), we also tested for the
sufficient expression of the SmBiT-tagged fusion constructs via Western blotting. Therefore,
we raised a polyclonal rabbit antibody against the SmBiT undecapeptide, which required
the aforementioned N-terminal cysteine for coupling of the SmBiT to the immunogenic
keyhole limpet hemocyanin. As the α-SmBiT antibody showed unspecific binding and the
occurrence of background bands, mock transfected cells served as negative control and
helped to verify the correct signal of the individual SmBiT-tagged fusion proteins. First,
the cytosolic control fusions cPKA-NS and Halo-CS were probed for abundance on protein
level. Both proteins provided an additional band in comparison to the mock transfected
cells and confirmed proper expression of the constructs (Figure 4). Likewise, the SmBiT
fusion proteins TRAPα-CS, TRAPβ-CS, Sec61α-CS, and Sec61β-NS could be detected using
the generated α-SmBiT antibody (Figure 4). We also generated two SmBiT fusions of
the much larger Sec63 protein, Sec63-CS and Sec63-NS. Neither of those two constructs
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could be detected with the α-SmBiT antibody. We attributed the lack of detection to the
more pronounced occurrence of unspecific cross-rations of the α-SmBiT antibody in the
molecular weight range above 40 kDa which might obscure efficient detection of the Sec63
fusion protein at approximately 100 kDa. Further, the use of polyclonal antibodies raised
against the native portion of the Sec63 fusion proteins did not provide an additional band of
higher molecular weight likely due to a combination of the small size of the SmBiT tag, the
intended low expression of fusion constructs, and partial masking of the antibody-epitope
by addition of the tag. The next alternative for testing expression of the SmBiT fusion
construct was to test their co-expression together with a LgBiT as part of a functional PPI
experiment. Luminescence arising from a combination of a LgBit and a SmBiT fusion
protein would indicate synthesis of both components as shown in the following section.
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Figure 4. Protein abundance levels of SmBit-tagged components using a tag-specific antibody.
Representative Western blot panels for different SmBiT fusion proteins twenty-four hours after
transfection of cells are shown. As indicated, lower panels were incubated with anti-β-actin antibody
as loading control and upper panels with the in-house generated anti-SmBiT antibody. Despite
multiple cross-reactions of the anti-SmBiT antibody (see mock transfected cells in lanes 1, 6, and
8), signals for SmBiT-tagged fusion proteins at the expected molecular weight can be identified
(arrowheads). Expected molecular weights: cPKA-CS (42 kDa), Halo-CS (36 kDa), TRAPα-CS
(38 kDa), TRAPβ-CS (28 kDa), Sec61α-CS (40 kDa), Sec61β-NS (13 kDa). CS, C-terminally located
SmBiT tag; NS, N-terminally located SmBiT tag.
2.5. α- and β-Subunit Interactions of the Sec61 or TRAP Complex
Next, we addressed the direct PPI of ER membrane protein pairs tagged with SmBiT
and LgBiT. As proof of concept, we tested the intra-complex interaction of the heterotrimeric
Sec61 complex. In its native environment, the Sec61complex consists of the channel-forming
Sec61α subunit flanked by the two tail-anchored subunits β and γ [44,45]. As depicted in
Figure 5A, we first tested if the cytosol facing N-termini of Sec61α and Sec61β are juxta-
posed and do interact. After transfection of cells with the corresponding reporter constructs
(Sec61α-NL, Sec61β-NS) and addition of the NanoLuc substrate luminescence was detected
(Figure 5B). As seen before for the cytosolic PKA constructs (Figure 1C), light emission for
the Sec61α-NL and S c61β-NS pair was p aking 4 min past furimazi e addition. To xclude
dra t c mislocalization of the constructs and verify that the Sec61α–Sec61β interactio oc-
curs intracell larly, cells were subjected to trypsin-mediated reporter degradation. Indeed,
only after permeabilization of th plasma membrane by digitonin, the lumin scent signal
was eliminated by addition of trypsin digesting the intracellular reporters. Instead, when
cells were treated with DMSO prior to trypsin, no sharp decline of luminescence could
be detected upon addition of the membrane impermeable protease (Figure 5B). Similar
to what was observed before, the mild digitonin treatment amplified luminescence likely
by providing easier access of furimazine to the cytosol (cf. Figures 1D, 2B and 5B). To
further substantiate the validity of the PPI between Sec61α and Sec61β, a strategy based
on competition was used. In addition to transfection with the reporter pair, cells received a
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third plasmid encoding an untagged, wild typic variant of either interaction partner. In
contrast to the reporter pair plasmids carrying the HSV-TK promotor, the plasmids used
for competition with untagged variants harbored a CMV promotor generally allowing
stronger expression of a downstream gene [46]. An empty vector (EV) transfection was
run in parallel and served as negative control. Contrary to the non-interacting Sec61α-NL
and Halo-CS pair, a strong luminescent signal was detected for both the Sec61α-NL and
Sec61β-NS pair as well as the Sec61α-NL and Sec61β-NS plus EV transfection (Figure 5C).
Notably, introducing either untagged Sec61α or Sec61β into the system luminescence of
the Sec61α-NL and Sec61β-NS reporter pair was strongly reduced and remained almost
at the background level of the negative control pair Sec61α-NL and Halo-CS (Figure 5C).
Thus, increasing the protein level of one of the interaction partners as untagged variant
significantly competed with the interaction of the tagged proteins and underlines the
authenticity of the tested Sec61α–Sec61β interaction in living cells at the ER (Figure 5D).
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and the corresponding biological replicates, the signals 4 min after furimazine addition were evaluated and plotted as
relative luminescent units (RLU). To do so, the luminescence of the negative control pair (Sec61α-NL plus Halo-CS) that
was run in parallel for each experiment was used for normalization and set to 1. To depict the variation of negative control
pair readings the average LU of this condition was used for its normalization. Statistical comparison of two conditions
was based on a student’s t-test (indicated by italic labels) and comparison of multiple conditions was done using ANOVA.
Vertical gray bars in the line diagrams represent manual 1 min application periods without luminescence readings. The
dotted lines are extrapolated based on the last and first data points before and after application. CS, C-terminally located
SmBiT tag; EV, empty vector; NL, N-terminally located LgBiT tag; ns, not significant; NS, N-terminally located SmBiT tag.
p-values are indicated by asterisks with p < 0.05 (*) or as non-significant (ns) if p ≥ 0.05.
We also tested the intra-complex PPI of the heterotetrameric TRAP complex. Three of
the four TRAP subunits (α, β, δ) traverse the ER membrane as single-pass type I membrane
protein. Together with the tetra-spanning γ subunit these four membrane proteins tightly
associate and form the native TRAP complex that supports as allosteric effector gating of the
Sec61 complex [14,15,40,47]. Regarding TRAP, we focused on the interaction between the α-
and β-subunit by generating the C-terminally tagged variants TRAPα-CL and TRAPβ-CS
(Figure 6A).
Consistent with the Sec61 complex, we subjected the TRAPα/β reporter pair to the
same luminescence measurements including trypsin-mediated reporter degradation and
competition with the untagged counterparts (Figure 6). When cells transfected with TRAPα-
CL and TRAPβ-CS were subjected to the furimazine–digitonin–trypsin, protocol we saw (i)
the direct interaction between TRAPα and TRAPβ, (ii) the amplified luminescence after
permeabilization of the plasma membrane, and (iii) rapid loss of the signal and PPI due to
the proteolytic digestion Figures 6B and S1B). Like the Sec61α/β reporter pair, also TRAPα-
CL and TRAPβ-CS showed a strong interaction in comparison to the non-interacting control
pair TRAPα-CL and Halo-CS (cf. Figures 5C and 6C). This interaction was further tested
using the competition setup based on plasmid-driven expression of the untagged TRAPA
or TRAPB gene. Increasing the protein level of TRAPα or TRAPβ caused a significant
reduction of the PPI between TRAPα-CL and TRAPβ-CS (Figure 6C,D). Furthermore, we
tested if the expression efficiency of the LgBiT reporter construct TRAPα-CL was impaired
by the additional expression of the untagged counterpart TRAPα or the presence of the EV
in the transfection mix. The underlying reason was that the addition of a third plasmid
during the transfection procedure might reduce transfection and/or expression efficiency of
the plasmids. As the exogenously added high-affinity HaBiT peptide was able to substitute
for and replace the genetically encoded SmBiT fusion construct of a given reporter pair, the
synthetic peptide complementation setup was used to test for expression of the TRAPα-CL
during transfections with two or three plasmids. As shown in Figure S3, the presence of
an additional plasmid in the mix was not affecting expression of the TRAPα-CL construct,
which still showed efficient complementation with HaBiT even in the presence of the
EV or of the plasmid encoding the untagged TRAPα protein. Compared to the negative
control pair TRAPα-CL and Halo-CS, all other three conditions combining TRAPα-CL with
TRAPβ-CS alone or in combination with either EV or TRAPα provided the same level of
luminescence upon addition of HaBiT (Figure S3B).
As Figures 5 and 6 showed the broad applicability of the BiLC approach for ER
membrane proteins, two questions arose. First, is the assay suited to detect inter-complex
interactions, for example between Sec61 and TRAP? Second, can the assay detect PPI arising
from reconstitution of the split luciferase either in the cytosol or the ER lumen? Detection
of luminescence emanating from the ER lumen would further prove the applicability of
the system to study PPI between membrane and/or soluble proteins occurring in the
ER lumen.
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Figure 6. Protein–protein interactions within subunits of the TRAP complex. (A) Topology cartoon of the presumed interac-
tion for the TRAPα-CL and TRAPβ-CS pair. Active luciferase is sy bolized as glo ing green/blue sphere. (B) Twenty-four
hours post transfection with the TRAPα-CL and TRAPβ-CS reporter pair, cells were subjected to the indicated treatments
(circled numbers). The furimazine treatment to activate luminescence (after 9 min) was fol o e tion
using digitonin (0.002 , after 19 i ) a try sin ediated reporter digestion (50 µg/mL, after 29 min). DMSO served
as vehicle control for digitonin. Measurements were normalized to the signal intensity recorded 4 min after furimazine
application. (C) BiLC was combined with competition. Twenty-four hours after double or triple transfection with the
indicated constructs, total luminescent units (LU) were measured. Consistency of the expression efficiency for double and
triple transfections was confirmed by synthetic peptide complementation (Figure S3). Protein names without a suffix do
not carry a tag and were designed to compete with the interaction of the tagged interaction partners. (D) Measurements
from (C) were used for quantification. For each condition and the corresponding biological replicates, the signals 4 min
fter furimazine addition were evalu ted and plotted as relative uminescent units (RLU). To do so, luminescence f the
nega ive control pair (TRAPα-CL plus Halo-CS) that was run in parall l for each experiment was used for normalization
and set to 1. To depict the variation of negative co trol pair readi gs, the average LU of this condition was used for its
normalization. Statistical comparison of two conditions was based on a student’s t-test (indicated by italic labels) and
comparison of multiple conditions was performed using ANOVA. Vertical gray bars in the line diagrams represent manual
1 min application periods without luminescence readings. The dotted lines are extrapolated based on the last and first data
points before and after application. CL, C-terminally located LgBiT tag; CS, C-terminally located SmBiT tag; EV, empty
vector; ns, not significant. p-values are indicated by asterisks with p < 0.01 (**) or as non-significant (ns) if p ≥ 0.05.
2.6. Inter-Complex Interactions between Sec61 and TRAP as well as Sec61 and Sec63
The generated set of fusion constructs was suited to address the questions of inter-
complex interaction as well as detection of ER luminal emitted luminescence. Based on
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the vicinity of the TRAP and Sec61 complex in native membranes of different organisms
and specimens, we first tested the inter-complex interaction between the α-subunits of
TRAP and Sec61 [15]. As before, cells were co-transfected with the reporter pair Sec61α-
NL and TRAPα-CS (Figure 7A). Co-transfection of cells with Sec61α-NL and Halo-CS
served as negative control. After addition of the luciferase substrate furimazine, strong
luminescence could be detected for the inter-complex interaction pair between Sec61α and
TRAPα, but not for the negative control (Figure 7B). To verify the specificity of the Sec61α–
TRAPα interaction in the native, cellular context additional complementation experiments
were carried out. In addition to the Sec61α-NL and TRAPα-CS reporter pair cells were
transfected with an EV or SEC61A1 encoding plasmid. In comparison to the additional
EV transfection the expression of the untagged SEC61A1 caused a significant reduction
of luminescence (Figure 7C). Thus, increasing the amount of untagged Sec61α competed
with the Sec61α-NL and TRAPα-CS interaction. This competition by the untagged Sec61α
protein substantiated the PPI of Sec61α and TRAPα in living cells.
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Excluding the positive and negative control based on the PKA reporter pair (Figure 
1), 35 combinations of LgBiT- and SmBiT-tagged proteins were tested and the signal in-
tensity of interactions is summarized as heatmap in Figure 8A. As proof of concept, we 
mostly focused on well-established interactions between proteins of soluble and mem-
brane-standing multimeric complexes like PKA, TRAP, and Sec61. Other than the interac-
tion of the cPKA and rPKA subunits, nine PPI of ER membrane proteins were identified 
(Figure 8A). Undoubtedly, difficult to control methodological constraints such as trans-
fection and expression efficiency of individual cells as well as transfection uniformity 
across a cell population can cloud deeper interpretation of the luminescence signal inten-
sity of a given PPI. Yet, it is tempting to consider the emitted light intensity as surrogate 
marker and as first approximation for the strength of a tested PPI. The three strongest, or 
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easurements, furimazine was added to activate luminescence. (C,F) Quantification and statistical analysis of luminescent
readings from (B,E). For each condition and the corresponding biological replicates, the signals 4 min after furimazine
addition were evaluated and plotted as relative luminescent units (RLU). Luminescence of the corresponding negative
control pair (Sec61α-NL plus Halo-CS in C; Sec61β-CL plus Halo-CS in (F)) that was run in parallel for each experiment
was used for normalization and set to 1. To depict the variation of negative control pair readings, the average LU of this
condition was used for its normalization, respectively. Statistical comparison of two conditions was based on a student’s
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t-test. Vertical gray bars in the line diagrams represent manual 1 min application periods without luminescence readings.
The dotted lines are extrapolated based on the last and first data points before and after application. CL, C-terminally
located LgBiT tag; CS, C-terminally located SmBiT tag; EV, empty vector; NL, N-terminally located LgBiT tag; ns, not
significant; NS, N-terminally located SmBiT tag. p-values are indicated by asterisks with p < 0.05 (*) or as non-significant
(ns) if p ≥ 0.05.
Next, we used a set of proteins whose LgBiT and SmBiT tags were both located in
the ER lumen and belong to different translocon subcomplexes, Sec61β-CL and Sec63-NS
(Figure 7D). When cells were co-transfected with the corresponding plasmids application
of furimazine indicated (i) the functionality of the ER luminally assembled luciferase
converting furimazine to furimamide plus light, and (ii) the inter-complex interaction
between Sec61β and Sec63 (Figure 7E). Analogous to the TRAPα–Sec61α interaction, the
Sec61β–Sec63 PPI was also susceptible to competition by expression of the untagged
interaction partner. When cells carrying the interaction pair Sec61β-CL and Sec63-NS were
transfected with a plasmid encoding wild type SEC61B, luminescence was much reduced
compared to the corresponding EV transfection (Figure 7F).
2.7. Sterically Impossible Complementations Set the Threshold for Authentic Protein Interactions
Excluding the positive and negative control based on the PKA reporter pair (Figure 1),
35 combinations of LgBiT- and SmBiT-tagged proteins were tested and the signal intensity
of interactions is summarized as heatmap in Figure 8A. As proof of concept, we mostly fo-
cused on well-established interactions between proteins of soluble and membrane-standing
multimeric complexes like PKA, TRAP, and Sec61. Other than the interaction of the cPKA
and rPKA subunits, nine PPI of ER membrane proteins were identified (Figure 8A). Un-
doubtedly, difficult to control methodological constraints such as transfection and expres-
sion efficiency of individual cells as well as transfection uniformity across a cell population
can cloud deeper interpretation of the luminescence signal intensity of a given PPI. Yet, it
is tempting to consider the emitted light intensity as surrogate marker and as first approxi-
mation for the strength of a tested PPI. The three strongest, or at least most light-intense,
interactions of ER membrane proteins included the intra-complex interaction between
Sec61α–Sec61β (141 RLU) and TRAPα–TRAPβ (91 RLU) as well as the inter-complex
interaction Sec61β–Sec63 (202 RLU). Compared to the 613 RLU measured for the soluble
rPKA–cPKA pair, those RLU are 3–6 times lower and might be explained by the limited
structural flexibility and/or local mobility of membrane proteins (Figure 8B). Including
those three, the validity of the five strongest PPI of ER membrane proteins was further
confirmed by competition experiments with untagged proteins and is highlighted in the
heatmap by check marks (Figures 5–7, 8A and S3A).
As addendum to the previous data with the LgBiT and SmBiT tags of fusion proteins
being located in the same compartment, the heatmap also features the sterically impossible
interactions pairs that were tested (Figure 8A, hachures). By definition, physical separation
of the reporter tags by a lipid bilayer should prevent their complementation. As assumed,
all ten tested pairs with LgBiT and SmBiT tags placed on opposite sides of the ER membrane
provided only background luminescence and, thus, served as reliable negative controls
to set the threshold value for a meaningful PPI above 10 RLU (Figure 8A hachures and
Figure 8B). In light of a potential degradation, mislocalization, or inverted orientation of
tagged membrane proteins, luminescence below threshold can provide useful information,
too. For example, the Sec61β-CL reporter represents a C-terminally extended tail-anchored
protein (cf. Figure 3A). Adding 176 aa (LgBiT plus linker) shifts the single TMH of Sec61β
from the C-terminus to the center of the protein and might affect topology [48–50]. On the
one hand, Sec61β-CL did not show interaction with the five tested cytosolic SmBiT variants
of proteins (Sec61α/β-CS, TRAPα/β-CS, Sec63-CS), most of which are known to associate
in close proximity to Sec61β in native membranes and, thus, speaking against an inverted
topology of Sec61β-CL [7,19,51]. Instead, steady-state synthesis of the Sec61β-CL protein
(Figure 4) as well as strong interaction with the luminally located Sec63-NS (Figure 7)
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were detected. On the other hand, of the sterically impossible interactions the Sec61β-CL
plus Sec61α-CS reporter pair provided the highest RLU with 8.2, which might indicate
a negligible fraction of Sec61β-CL proteins oriented in an inverted topology (Figure 8B).
Based on these data, we considered 10 RLU as a reasonable threshold to differentiate
between the luminescence of an unspecific interaction (RLU < 10) and that of valid PPI of
ER membrane proteins (RLU > 10).




Figure 8. Summary of protein–protein interactions measured in living mammalian cells. (A) Heatmap summarizing the 
tested PPI. Interaction strength is based on relative luminescence units (RLU) normalized to the negative control Halo-CS 
set as 1 and shown in the first column. RLU below 10 were considered as background (gray color). In addition to the RLU-
based interaction strength, the heatmap encodes (i) if a given PPI could be confirmed by competition experiments 
(checkmark symbols, cf. Figures 5–7) and (ii) if the interaction of the tested reporter pair is sterically impossible, i.e., the 
tags are oriented on different sides of the ER membrane (hachured squares). (B) Data summary of tested PPI pairs as 
average ± standard error of the mean from (n) tested replicates. For better comparison, layout of the grid and heatmap in 
panel A are identical. (C) Interaction network based on the five proteins of interest tested here. While thickness of con-
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Using a split luciferase and the principle of BiLC, multiple PPI of ER membrane pro-
teins were probed in living cells. The luciferase used here represents an optimized variant 
of the catalytic subunit of the deep sea luminous shrimp (Oplophorus gracilirostris) enzyme 
and was called NanoLuc. The original 27 aa long signal peptide was substituted by the 
MV dipeptide. While the wild type luciferase had one cysteine residue close to the C-
terminus, mutational analysis of the SmBit tag replaced this cysteine by phenylalanine 
[37,38]. Thus, despite the presence of protein disulfide isomerases and the oxidative envi-
ronment found in the ER, the lack of cysteine residues in the NanoLuc should allow 
proper assembly of the functional monooxygenase also in this compartment. Indeed, lu-
minescence of the re-assembled luciferase could be detected in the cytosol as well as the 
ER lumen. The latter was demonstrated by the Sec61β–Sec63 interaction. This interaction 
demonstrated (i) the efficient reconstitution of the functional luciferase in the ER lumen 
as well as (ii) that the oxygen- and furimazine-dependent luminescence is not blocked by 
Figure 8. Summary of protein–protein interactions measured in living mammalian cells. (A) Heatmap summarizing the
tested P I. Interaction strength is based on relative luminesc nce units (RLU) normalized to the negative contr l Halo-CS set
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Taken together, BiLC provided a robust and versatile method to detect topology-
dependent PPI of various ER membrane proteins including associations within heteromul-
timeric complexes such as TRAP or Sec61 as well as inter-complex subunit connections
between Sec61 and TRAP or Sec61 and Sec63/Sec62. Authenticity of the described interac-
tions was further corroborated by competition experiments. Increasing the protein level of
one of the interaction partners as untagged protein reduced luminescence, i.e., PPI.
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3. Discussion
Using a split luciferase and the principle of BiLC, multiple PPI of ER membrane pro-
teins were probed in living cells. The luciferase used here represents an optimized variant
of the catalytic subunit of the deep sea luminous shrimp (Oplophorus gracilirostris) enzyme
and was called NanoLuc. The original 27 aa long signal peptide was substituted by the MV
dipeptide. While the wild type luciferase had one cysteine residue close to the C-terminus,
mutational analysis of the SmBit tag replaced this cysteine by phenylalanine [37,38]. Thus,
despite the presence of protein disulfide isomerases and the oxidative environment found
in the ER, the lack of cysteine residues in the NanoLuc should allow proper assembly of
the functional monooxygenase also in this compartment. Indeed, luminescence of the
re-assembled luciferase could be detected in the cytosol as well as the ER lumen. The latter
was demonstrated by the Sec61β–Sec63 interaction. This interaction demonstrated (i) the
efficient reconstitution of the functional luciferase in the ER lumen as well as (ii) that the
oxygen- and furimazine-dependent luminescence is not blocked by the presence of an
additional membrane or the milieu of the mammalian ER lumen (Figure 7D–F). However,
future experiments will test more PPI for which the topological layout of the reporter pair
requires reconstitution of the split luciferase in the ER lumen. In addition, considering the
N-terminal signal peptide of the original shrimp luciferase, at least the wild typic version
of the enzyme was adapted to the secretory pathway.
Dynamic adaptability and reversibility of PPI in living cells was demonstrated for
assembly of the PKA subunits using forskolin as an activator of the adenylate cyclase
(Figure 1). Thus, the system will be well suited to address the dynamics of the detected
translocon interactions under different cellular conditions or perturbations. For instance,
Snapp and colleagues designed a FRET assay that was used to detect ribosome associations
of translocon proteins via antibody accessibility before and after RNase A treatment [52,53].
Instead of trypsin-mediated reporter degradation (Figures 1D, 5B and 6B, RNase A can
be used upon semi-permeabilization to test either alterations in the PPI patterns of intra-
and inter-complex associations or the efficiency of the synthetic complementation with the
SmBiT and HaBiT peptide. Similarly, but without the necessity of semi-permeabilization,
the effect of specific ribosomal or translocon inhibitors mimicking different stages of the
protein transport process can be tested [54–57].
Luminescence data from the heatmap (Figure 8A) are also displayed as interaction
network summarizing the intra- and inter-complex PPI of the five ER proteins tested here
(Figure 8C). Even on this small scale some central nodes and connections within the holo-
translocon become evident. As expected, Sec61α represents a major node with connections
to Sec61β, TRAPα, and Sec63. All of those Sec61α-related connections have previously been
observed by X-ray crystallography, cryo-electron microscopy/tomography, native gel elec-
trophoresis, co-immunoprecipitation, or cross-linking studies [10,12,15,58–63]. However,
none did so in living mammalian cells. Intriguingly, using different types of substrates
the existence, and eventually dynamic assembly, of substrate-matched translocon sub-
complexes was demonstrated [9]. As proposed earlier, the RLU measured in living cells
might be indicative of the strength and permanency of a given PPI. This idea fits reasonably
well with both cross-linking data and in situ structures. While the Sec61α–Sec61β (141 RLU)
pair is consistently observed being associated, the Sec61α–TRAPα (62 RLU) association
was seen to dissipate when substrates like prion protein or ERj3 engaged the translocon. In
turn, those substrates, which probably present a minor fraction of the totality of transported
cargos, rather stimulate the Sec61–Sec63 complex formation in mammalian settings [9].
Accordingly, we found Sec61α–Sec63 as weak or transiently interacting pair with only
17 RLU. Based on the recent structural data from the yeast translocon, the Sec61 complex
and Sec63/Sec62 module assemble to form a translocon for the post-translational protein
transport, a mode of transport less frequently encountered in mammalian cells [16,64,65].
Yet another recent structure of the fully closed yeast Sec complex from the Park lab shows
juxtaposition of the Sec61β C-terminus and Sec63 N-terminus in the ER lumen [66]. While
we measured only a weak association between Sec61α and Sec63, it was the reporter pair of
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Sec61β C-terminus and Sec63 N-terminus that provided strong luminescence of 202 RLU
(Figure 8B). Maybe Sec61β acts as the mediator that keeps Sec63 in vicinity of the Sec61
complex during transport events not relying on the Sec63/Sec62 module. Once substrates
with special requirements start the gating process, Sec61β allows rapid integration of Sec63
into the active translocon. If so, Sec61β and Sec63 eventually will show a partially overlap-
ping substrate-spectrum, which remains to be seen [6,18,67]. This scenario is reminiscent
of a previous report showing the recruitment of the signal peptidase complex to the active,
ribosome-engaged translocon by Sec61β [68].
TRAPα emerged as a second node in the interaction network. Aside from the interac-
tion with Sec61α discussed before, TRAPα interacted strongly with its complex partner
TRAPβ (91 RLU). Biochemical purifications identified the TRAP complex as a hetero-
tetramer with the four subunits α-δ in a 1:1:1:1 stoichiometry [40,69,70]. Interestingly, using
an appropriate pair of constructs the BiLC approach can also identify homo-oligomers,
which we found for TRAPα, but not TRAPβ or Sec61α (Figure 8A–C). Based on the bi-
molecular design of the assay, it is unclear if two TRAPα molecules from adjacent TRAP
complexes interact or if TRAPα forms a dimer or even a multimer within the same TRAP
complex. Consequently, it will be intriguing to check if the TRAPα/β volume in the ER
lumen defined by in situ structures of the mammalian TRAP complex could accommodate
for more than one TRAPα protein [14,15,62].
In sum, luminescence complementation provided multiple interactions of subunits
of the ER protein translocase in living cells (Figure 8D). Ease of use and expandability
of the set of constructs plus the combination of the system with biological and synthetic
agents will help to examine the dynamics of ER membrane proteins under different cellular
conditions or in different cell lines (Figure S4).
4. Materials and Methods
4.1. Creation of a Plasmid Library
To clone the different reporter constructs four different backbone plasmids (X-NS,
X-NL, X-CS, X-CL) for the insertion of cDNA were used. Backbone plasmids as well as the
three control plasmids encoding for rPKA-CL, cPKa-CS, and Halo-CS were provided as
part of the NanoBiT PPI Starter System (Promega, Madison, WI, USA). To insert cDNA
encoding for a protein of interest a standardized workflow was used. Forward and reverse
primers were designed that anneal to the 5′- and 3′-end of the cDNA (Table S1). Primer
overhangs included restriction sites for subcloning of cDNA into the multiple cloning
site of the backbone vectors. After purification of the PCR product with QIAquick PCR
purification kit (Qiagen, Hilden, Germany) the cleaned PCR product and backbone plasmid
were double digested for directed insertion via sticky ends. Fragments were separated
on agarose gels and purified via the QIAquick gel extraction kit (Qiagen). Insert and
plasmid were ligated in a 3:1 ratio for 1 h at room temperature using T4 ligase (Thermo
Fisher, Waltham, MA, USA). The ligation product was used for heat-shock transformation
(42 ◦C for 90 s) of JM101 E. coli cells, which were plated on a 100 µg/mL ampicillin/LB-
agar plate. After 16 h single colonies were picked and grown in a 2 mL liquid culture
using 100 µg/mL ampicillin/TB medium. Cultures were harvested by centrifugation in a
table-top centrifuge (3000 rpm, 5 min) and plasmid DNA was purified using the PureYield
Plasmid Miniprep System (Promega). All plasmids were verified by sequencing (LGC
Genomics, Berlin, Germany) and subsequently amplified in the DH5α E. coli strain after
heat shock transformation (42 ◦C for 45 s). Plasmids from a 100 mL ampicillin/LB medium
culture were purified using the Plasmid Midi Kit (Qiagen).
4.2. Cell Culture and Western Blot
Cell culture experiments were performed using HeLa ATCC no. CCL2 cells. The cells
were cultivated in standard DMEM + GlutaMAX media with 10% FCS and 1% Pen/Strep
(Thermo Fisher) in a humid environment at 37 ◦C and 5% CO2. To prepare samples for
Western blot 6 × 105 cells were seeded in a 6 cm dish (GreinerBioOne, Frickenhausen, Ger-
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many) and cultivated for 24 h before plasmid transfection. Amounts of 190 µL Opti-MEM
(Thermo Fisher), 2 µL DNA (1 µg/µL), and 8 µL FuGeneHD (Promega) were mixed and
incubated for 10 min at room temperature. The transfection mixture was added dropwise to
cells, which were refreshed by 4 mL media beforehand. After 24 h cells were washed with
PBS (Thermo Fisher), trypsinized (Trypsin-EDTA, Thermo Fisher) and harvested in 2 mL of
KHM buffer (110 mM potassium acetate, 2 mM magnesium acetate, 20 mM HEPES/KOH,
pH 7.2) plus 125 µg/mL trypsin inhibitor (MP Biomedicals, Illkirch-Graffenstaden, France).
Cells were counted with the Countess Automated Cell Counter (Invitrogen, Darmstadt,
Germany) and semi-permeabilized as described before [71]. Samples were mixed with
Laemmli buffer (60 mM Tris/HCl pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) 2-
mercaptoethanol, 0.01% (w/v) bromophenol blue), and denatured at 56 ◦C for 10 min. A
total of 2 × 105 cells were loaded on an SDS-PAGE gel, followed by transfer on a PVDF
membrane (Merck Millipore, Billerica, MA, USA). Membranes were blocked for 30 min
with 3% (w/v) BSA (Roth, Karlsruhe, Germany) dissolved in TBS (150 mM NaCl, 10 mM
Tris/HCl pH 7.4). Afterwards, the membrane was incubated for 90 min each with primary
and secondary antibodies diluted in blocking solution. After every antibody incubation
the membrane was washed four times for 5 min using TBS as first and last washing step
and TBS-T (TBS plus 0.005% Tween-20 (Sigma-Aldrich, Steinheim, Germany)) in between.
The membrane was dried and scanned by the Typhoon Trio (GE Healthcare, Uppsala,
Sweden). The following peptide was used to raise the primary antibody against the SmBiT
tag (CVTGYRLFEEIL). The β-actin antibody (Sigma-Aldrich) was used as loading control.
Visualization of primary antibodies was done using ECL Plex goat anti-rabbit IgG-Cy5
(VWR, Radnor, PA, USA) or ECL Plex goat anti-mouse IgG-Cy3 (GE Healthcare) and the
Typhoon-Trio imaging system in combination with the ImageQuant TL software version
7.0 (GE Healthcare, Uppsala, Sweden).
4.3. NanoBiT Assay
Per cavity of a white, flat-bottom 96-well plate (GreinerBioOne) 2 × 104 cells were
seeded in 100 µL media and cultivated for 24 h in the incubator. Transfection with the
reporter constructs was performed without previous media exchange according to Table 1.
The transfection mix was incubated at room temperature for 10 min and added to the wells.
Per well per plasmid 50 ng of the DNA construct was used. After incubation for 24 h and
5 min before start of the measurement, the medium was replaced with prewarmed Opti-
MEM without phenol red (Thermo Fisher) and the 96-well plate was placed in the preheated
microplate reader (Tecan Infinite M200). Luminescence was recorded with the following
settings: interval 1 min; shaking before every interval; integration time 1000 ms; settle time
50 ms. To activate the luciferase, 20 µL of the 1:20 diluted Nano-Glo Live Cell Assay System
(Promega) were added according to manufacturer’s protocol. Substances were added at
the indicated timepoints in the figures with the following final concentrations: Digitonin
(Merck, Darmstadt, Germany), 0.002%; Forskolin (Sigma-Aldrich), 15 µM; Peptides (see
below), 10 pM–100 µM; RNase A (Roche, Basel, Switzerland), 80 µg/mL; Trypsin (Roche),
50 µg/mL. Stocks of digitonin, forskolin, and peptides were dissolved in DMSO (Sigma-
Aldrich) whereas RNase A and trypsin were dissolved in H2O. Stocks and solvents as
negative control were prediluted in Opti-MEM without phenol red.
4.4. Peptide Synthesis
Peptides were synthesized with an automated ResPepSL synthesizer (Intavis, Cologne,
Germany) using amide Rink resin as the solid phase and Fmoc-protected amino acids
(Carbolution, St. Ingbert, Germany) for coupling according to the method of Merrifield [72].
The resin-coupled peptides were cleaved and deprotected with trifluoroacetic acid (Sigma-
Aldrich) followed by precipitation with tert-butyl methyl ether (Thermo Fisher) and further
analysis and purification by preparative HPLC (Merck, Darmstadt, Germany). Lyophilized
peptides (Lyovac GT2, Finn-Aqua, Tuusula, Finland) were stored at 4 ◦C. Stock solutions
of the peptides were prepared fresh and used the same day.
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Table 1. Composition and intended purpose of different plasmid transfection mixtures. Stock concentrations of the plasmids
were 100 ng/µL. All volumes are provided in microliters.







w/o phenol red 7.36 6.72 6.08
LgBit plasmid 0.50 0.50 0.50
SmBiT plasmid - 0.50 0.50
Competition plasmid - - 0.50
FuGENE HD 1 0.14 0.28 0.42
1 FuGENE HD (Promega).
4.5. Antibody Generation
Synthesized peptides were coupled to maleimide-activated keyhole limpet haemo-
cyanin via an N- or C-terminal cysteine for 16 h at room temperature. After size exclusion
chromatography, the protein fraction was dialyzed excessively with physiological buffer
solution (137 mM NaCl, 2.7 mM KCl,10 mM Na2HPO4, 1.8 MM KH2PO4, pH 7.4). Rabbits
were immunized subcutaneously in 250 µL doses (100 µg antigen/Freud’s Adjuvant) at
14-day intervals. Blood was collected at 8-day intervals after each immunization. The
serum was prepared after agglutination by several 10-min centrifugation steps at 4 ◦C in a
table-top centrifuge.
4.6. Statistics and Graphical Representation
Graphs were visualized using Sigma Plot 14.0 (Systat Software GmbH, Erkrath, Ger-
many) and Corel Draw Graphics Suite 2018 software (Coral Cooperation, Ottawa, Canada).
Statistical comparison of multiple groups was performed using ANOVA in combination
with Dunnett’s multiple comparison test whereas two groups were compared based on an
unpaired, two-tailed t-test. p-values are indicated by asterisks with p < 0.001 (***) < 0.01 (**)
< 0.05 (*) or as non-significant (ns) if p≥ 0.05. For better differentiation, the p-value symbols
emanating from a t-test are written in italic in bar graphs. The number of repeats for each
experiment are indicated by the individual data points shown in the bar graphs.
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